Smoking Cessation Intervention for Thoracic Patients
The primary aim of the proposed study is to develop and assess the feasibility of delivering a smoking cessation intervention to patients undergoing lung surgery that begins before surgery and continues up to 3 months post-discharge. The secondary aim is to assess smoking cessation rates 3 months following surgery.
Checked against the public recordLast updated Oct 12, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Massachusetts General Hospital
- Interventions being studied
- Behavioral: Smoking cessation counseling; Drug: varenicline
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: A patient is eligible if he/she: 1. Is scheduled for a lung resection surgery with either a lung cancer diagnosis or a potential lung cancer diagnosis 2. Smoked a cigarette in the past 2 weeks 3. Is willing to make a pre-surgical quit attempt Exclusion Criteria: Patients will be excluded from the intervention group if they are: 1. Non-English speaking 2. Determined medically ineligible by their surgeon 3. Suffering from psychosis or dementia 4. Have been taking Varenicline for longer than three weeks 5. Have been taking Bupropion (for smoking cessation purposes) for more than three weeks 6. Is otherwise unable to participate in the intervention.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Massachusetts General HospitalBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 12, 2018. Always confirm current availability with the study team.